From: Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
Total | PF-ILD | Non-PF-ILD | P-value | |
---|---|---|---|---|
Number of patients | 396 | 135 | 261 | |
Age, years | 58.1 ± 10.6 | 58.7 ± 10.1 | 57.9 ± 10.8 | 0.474 |
Male | 158 (39.9) | 58 (43.0) | 100 (38.3) | 0.388 |
BMI, kg/m2 | 23.8 ± 3.3 | 24.3 ± 3.6 | 23.6 ± 3.1 | 0.074 |
Ever-smokers | 163 (41.2) | 56 (41.5) | 107 (41.0) | > 0.999 |
ILD subtype | 0.328 | |||
iNSIP | 76 (19.2) | 20 (14.8) | 56 (21.5) | |
HP | 52 (13.1) | 29 (21.5) | 23 (8.8) | |
RA-ILD | 168 (42.4) | 58 (43.0) | 110 (42.1) | |
SSc-ILD | 54 (13.6) | 18 (13.3) | 36 (13.8) | |
SJS-ILD | 46 (11.6) | 10 (7.4) | 36 (13.8) | |
PFT, % predicted | ||||
FVC | 73.3 ± 16.6 | 70.5 ± 16.5 | 74.7 ± 16.5 | 0.016 |
DLCO | 62.4 ± 18.0 | 60.0 ± 16.7 | 63.6 ± 18.6 | 0.059 |
TLC | 74.9 ± 14.8 | 71.7 ± 13.6 | 76.6 ± 15.1 | 0.002 |
HRCT pattern | 0.750 | |||
UIP-like pattern | 181 (45.7) | 60 (44.4) | 121 (46.4) | |
Non-UIP-like pattern | 215 (54.3) | 75 (55.6) | 140 (53.6) | |
Treatment | 0.078 | |||
Steroid ± IMa | 365 (92.2) | 129 (95.6) | 236 (90.4) | |
No treatment | 31 (7.8) | 6 (4.4) | 25 (9.6) |